Selenocysteine inhibits human osteosarcoma cells growth through triggering mitochondrial dysfunction and ROS-mediated p53 phosphorylation
| Autor: | Wei, Wang, Fan-Bin, Meng, Zhen-Xing, Wang, Xiao, Li, Dong-Sheng, Zhou |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Osteosarcoma
Mice Nude Antineoplastic Agents Apoptosis Bone Neoplasms Xenograft Model Antitumor Assays Mitochondria Selenocysteine Proto-Oncogene Proteins c-bcl-2 Cell Line Tumor S Phase Cell Cycle Checkpoints Animals Humans Phosphorylation Tumor Suppressor Protein p53 Reactive Oxygen Species Cell Proliferation |
| Zdroj: | Cell biology international. 42(5) |
| ISSN: | 1095-8355 |
| Popis: | Osteosarcoma represents the most common primary malignant bone tumor in children and adolescents, which shows severe resistance toward standard chemotherapy because of high invasive capacity and growing incidence. Selenocysteine (SeC) is a naturally available Se-containing amino acid that displays splendid anticancer activities against several human tumors. However, little information about SeC-induced growth inhibition against human osteosarcoma is available. Herein, the anticancer efficiency and underlying mechanism of SeC against human osteosarcoma were evaluated in vitro and in vivo. The results revealed that SeC significantly inhibited MG-63 human osteosarcoma cells growth in vitro through induction of S-phase arrest and apoptosis, as reflected by the decrease of cyclin A and CDK-2, PARP cleavage, and caspases activation. SeC treatment also resulted in mitochondrial dysfunction through affecting Bcl-2 family expression. Moreover, SeC triggered p53 phosphorylation by inducing reactive oxygen species (ROS) overproduction. ROS inhibition effectively blocked SeC-induced cytotoxicity and p53 phosphorylation. Importantly, MG-63 human osteosarcoma xenograft growth in nude mice was significantly suppressed in vivo through triggering apoptosis and p53 phosphorylation. These results indicated that SeC had the potential to inhibit human osteosarcoma cells growth in vitro and in vivo through triggering mitochondrial dysfunction and ROS-mediated p53 phosphorylation, which validated the potential application of Se-containing compounds in treatment of human osteosarcoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text